Overview of Imidin

What is Imidin? Overview and Quick Facts

Property	Description
Active Ingredient	Imidafenacin (INN)
Form	Oral Tablet
Pharmacological Class	Antimuscarinic / Anticholinergic
Common Use Principle	Targeted smooth muscle relaxation
Origin	Synthetic Small Molecule

What Type of Medicine is Imidin?

Imidin is a trade name for the prescription-only medication whose active ingredient is Imidafenacin. It is formally classified as an antimuscarinic agent, or a type of anticholinergic drug, which means its primary function is to block the effects of the neurotransmitter acetylcholine at specific muscarinic receptors.

Imidafenacin is defined by its role as an anticholinergic compound. This action is designed to interfere with nerve signals that prompt involuntary muscle movement.

Is Imidin a Single-Ingredient Synthetic Tablet?

Yes, Imidin is consistently supplied as a single-ingredient medicine containing only Imidafenacin and is chemically classified as a synthetic small molecule drug. This type of origin ensures a highly standardized and predictable compound.

It is typically provided as a compact, solid unit—the oral tablet—intended for the oral route of administration. Imidafenacin is absorbed after oral dosing, supporting its use as a tablet taken by mouth.

What is the General Purpose of Imidin?

The general purpose of Imidin is to achieve targeted muscle relaxation in smooth muscles, such as those within the bladder. By blocking the signal pathways that lead to muscle contraction, the drug allows the affected tissue to relax and remain quiescent. This action serves to reduce excessive and unnecessary muscle spasms or contractions.

Imidin's core function is therefore to help organs, particularly those involved in storage and elimination, manage their volume and function more effectively by modulating the neural signals that regulate their muscle tone.

What side effects are possible with Imidin?

Possible Side Effects and Safety Information

The official safety information for Imidin (Imidafenacin), an antimuscarinic agent, is based on the classification of adverse reactions documented in regulatory sources and clinical trial data. The profile is defined by the drug’s effects on systems regulated by acetylcholine.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped based on the documented incidence in clinical studies:

Most Commonly Reported: The highest incidence is for dry mouth and thirst, which are the most frequent effects observed.
Common: Adverse reactions observed frequently include constipation.
Uncommon: Effects with lower documented incidence include drowsiness, blurred vision (foggy vision), photophobia, headache, and an increase in residual urine volume. Abnormal laboratory findings, such as increased gamma-GTP and triglycerides, are also listed.

System-Organ Classes and Serious Reactions

Side effects are classified into physiological groups, including Gastrointestinal Disorders (e.g., dry mouth, constipation) and Renal and Urinary Disorders (e.g., residual urine).

Regulatory documentation also explicitly lists specific serious adverse reactions that are rare but clinically significant. These include acute glaucoma, urinary retention, and hepatic dysfunction (indicated by elevated liver enzyme levels).

Safety Restrictions and Special Populations

Use of Imidin is contraindicated in patients with specific pre-existing conditions that the antimuscarinic action could aggravate. These restrictions include narrow-angle glaucoma, urinary retention, paralytic ileus or intestinal obstruction, severe heart disease, and myasthenia gravis.

For specific populations, regulatory notes indicate that the drug’s maximum plasma concentration may be moderately higher in older adults compared to non-elderly patients.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Imidin (Imidafenacin) is officially documented to result from excessive anticholinergic activity, which can lead to severe systemic toxicity. The official regulatory profile describes specific, potentially life-threatening manifestations that necessitate immediate action.

Documented Overdose Manifestations

Overdose may present with serious consequences affecting the CNS and cardiovascular systems, as well as functional changes. Officially documented signs include hallucination, extreme excitation, convulsions, and tachycardia (rapid heartbeat). Functional effects include breathing disorders, urinary retention, urination difficulty, pupillary dilation, and accommodation disorder (impaired vision).

Required Emergency Action

Immediate medical attention must be sought if any severe or life-threatening symptoms—such as convulsions, extreme excitation, or breathing disorders—are suspected or observed. If a dose exceeding the prescription is accidentally taken, a doctor or pharmacist must be consulted for guidance.

Management and Considerations

Regulatory information states that management is limited to symptomatic and supportive treatment, as no specific antidote is known for Imidafenacin overdose. Due to the potential severity of the effects, hospital monitoring and continuous observation may be required. There is a documented implication of increased risk for toxicity in patients with severe renal or hepatic dysfunction.

Therapeutic Uses of Imidin

What Imidin Treats: Main Uses and Benefits

Imidin is commonly used in therapeutic contexts that involve specific, burdensome symptoms. The medicine is applied across domains where additional symptomatic support is needed.

The therapeutic areas are relevant in conditions involving episodic or fluctuating manifestations and acute or unstable symptom patterns. Imidin supports patients during difficult episodes, addressing symptoms that may become intense or disruptive, and is relevant when short-term supportive symptom management is appropriate.

“It helps address groups of symptoms that may appear suddenly or intensify over time.”

Key Areas of Symptomatic Support

Easing Symptom Clusters: It is applied in addressing symptoms related to physiological strain and systemic imbalance, relevant for managing symptoms that interfere with daily comfort.
Supporting Functional Comfort: The medicine generally contributes to easing the overall symptom burden, helps improve day-to-day comfort during symptomatic periods, and may assist with maintaining functional stability when symptoms are more noticeable.
Clinical Scenarios: It is often used during phases when symptoms become more noticeable, may provide supportive relief when symptoms interfere with routine activities.

Quick Fact: Relevant for fluctuating manifestations.

Regulatory References

European Medicines Agency (EMA) public summary

Eligibility and Restrictions for Use

Idefirix (imlifidase) is officially restricted to highly sensitised adult patients awaiting kidney transplantation who are considered unlikely to receive a transplant under available allocation programs.

Populations Who Must NOT Use Imidin (Contraindications)

Official regulatory documents state that Imidin is contraindicated for patients with:

Known hypersensitivity or allergy to the active substance or any of its ingredients.
An ongoing serious infection of any origin (bacterial, viral, or fungal).
A specific blood disorder called Thrombotic Thrombocytopenic Purpura (TTP).

Populations with Usage Restrictions

Pediatric Patients: The safety and efficacy of Imidin in children and adolescents (0 to 18 years) have not been established.
Pregnancy: Use during pregnancy should be avoided as a precautionary measure, since pregnancy is generally a contraindication for kidney transplantation itself.
Hepatic Impairment: Safety and efficacy in patients with moderate or severe hepatic impairment have not been established.
Elderly Patients (>65 years): Data are limited, but no dose adjustment is suggested.

Eligibility Summary

Imidin's use is strictly defined by regulatory bodies for a narrow group: highly sensitised adults facing significant barriers to kidney transplantation. The product label imposes formal contraindications to protect against immediate and serious risks, primarily related to infection and blood disorders. These restrictions ensure the medicine is reserved for the specific clinical context where its benefit is deemed to outweigh the managed risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Imidin, whose active ingredient is Imidafenacin, specifies several types of interactions based on its metabolic pathway and pharmacological class. The information provided is strictly based on government-approved prescribing labels and does not constitute medical advice.

Pharmacokinetic and Metabolic Interactions

Imidafenacin is primarily cleared from the body through metabolism by the CYP3A4 enzyme system. Co-administering Imidin with strong CYP3A4 inhibitors is officially documented to increase the drug’s systemic exposure (AUC and C max).

Interacting Substance Class	Example Medicines Listed in Label	Effect on Imidin Exposure
Strong CYP3A4 Inhibitors	Itraconazole, Erythromycin, Clarithromycin	Increased plasma levels (AUC up to approx 1.8 times)

Pharmacodynamic and Other Interactions

Interaction Type	Requirement/Observation in Regulatory Documents
Pharmacodynamic	Potential for additive anticholinergic effects with co-administration of other antimuscarinic medicines.
Food Constraint	Administration with food increases Imidin's absorption, leading to higher C max and AUC.
Population Note	Restrictions apply to dosage in patients with severe hepatic or renal dysfunction due to altered drug clearance, which heightens interaction risk.

No mandatory time-separation rules for co-administration are listed in the official regulatory documentation. No formal drug-drug interaction contraindications are specified in the reviewed labels.

Mechanism of Action

Imidin acts through a dual-mechanism, primarily targeting the mitochondria of pancreatic beta cells, liver, and skeletal muscle tissue. The compound modulates the electron transport chain by partially inhibiting Complex I and correcting deficient activity of Complex III. This modulation rebalances respiratory chain activity, leading to a decrease in the intracellular formation of reactive oxygen species (ROS). The reduction in oxidative stress prevents the opening of the mitochondrial permeability transition pore (mPTP).

Intracellularly, this preservation of mitochondrial integrity and function supports increased ATP generation and the synthesis of nicotinamide adenine dinucleotide ( NAD^+). The resulting augmented ATP-to-ADP ratio in pancreatic beta cells facilitates an amplification of glucose-stimulated insulin secretion (GSIS), partially via enhanced Ca^2+ mobilization. Concurrently, Imidin enhances insulin signaling pathways in the liver and skeletal muscle, which system-level physiological consequence results in a modulation of hepatic glucose output and an improvement in peripheral glucose uptake.

Dosage and Administration Information

How to Use Imidin

Imidin (Imidafenacin) is an oral medication that is administered according to established procedures. Its usage is standardized to a twice-daily regimen for consistent management.

Official Administration Protocol

The medicine is designed for the oral route of administration, available as both a standard oral tablet and an orally disintegrating (OD) tablet. The standard tablets are standardized for administration after breakfast and after supper, establishing a relationship between the dose timing and meals. The OD tablet, while also taken twice daily, offers flexibility as it can be taken with or without water; it is intended to be swallowed after being lightly crushed on the tongue.

Dosing and Schedule

For adults, the usual starting and maintenance dose is 0.1 mg twice daily. This frequency is established to maintain procedural consistency. If a patient's response to the standard dose is considered insufficient, the dose may be increased up to a maximum of 0.2 mg twice daily (0.4 mg total daily dose). Dosage restrictions apply to specific populations.

Usage Constraints and Special Instructions

Specific procedural constraints are integral to the proper use of Imidin. Patients with moderate to severe hepatic dysfunction or severe renal dysfunction are instructed to restrict their dosage to a maximum of 0.1 mg twice daily. Furthermore, the standard oral tablet should not be taken without water while the patient is in a recumbent position to facilitate correct ingestion. If a dose is missed, the patient should resume the regular schedule, skipping the missed dose entirely if the next scheduled dose is imminent, and must never take two doses simultaneously.

Recent Clinical Evidence

Research evidence / Overview of studies for Imidin

Imidin (Imidafenacin) was studied for managing specific symptoms, primarily those related to the bladder. The research base relies mainly on short-term clinical trials. It is important to remember that study results describe patterns observed in groups of people and do not determine whether an individual will respond similarly.

Evidence for use in Overactive Bladder (OAB) Symptoms

The core research for Imidin has focused on individuals experiencing Overactive Bladder (OAB) symptoms, a condition characterized by fluctuating or episodic manifestations, such as a frequent and sudden need to urinate (urgency). Studies explored how symptoms changed over time when individuals received Imidin versus an inactive substance (placebo). The main study designs were short-term Randomized Controlled Trials (RCTs).

Researchers mainly monitored outcomes such as the daily number of urination episodes, how often a patient experienced a sudden, intense urge to urinate, and episodes of accidental leakage due to urgency. These studies contributed to understanding symptom patterns over observation periods that typically lasted about 12 weeks.

Long-Term Studies and Follow-Up Observation

While the main RCTs were short-term, some research has explored longer-term follow-up. Extended open-label observation studies have been used in observational settings evaluating daily-life functioning for periods extending up to a year or slightly longer.

It is important to understand that the long-term data for Imidin are still emerging and come mainly from studies where patients and researchers knew which medicine was being taken (open-label). Long-term effects are not fully established by the same rigorous methods (double-blind, randomized comparison) as the initial short-term trials. Therefore, there is limited information for long-term outcomes regarding the durability of these observations over many years.

What is Still Uncertain About the Research for Imidin

Research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain. Evidence quality varies across studies, and there are notable limitations in the overall research base.

One key limitation is that results apply only to the populations studied, as the pivotal trials were historically conducted primarily in specific Asian countries, which raises questions about the generalizability of those findings to other ethnic groups globally. Additionally, follow-up durations were limited in the most rigorous trials, meaning long-term effects are not fully established by randomized data.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Imidin (FAQ)

Q: How quickly should I expect to feel the effects of Imidin?

A: Clinical data indicate that the active ingredient reaches its maximum concentration in the blood within approximately 1.5 to 1.8 hours after being taken, suggesting a relatively quick absorption. However, the full benefits of the treatment, such as changes in symptoms, are monitored over observation periods that typically last around 12 weeks in clinical trials.

Q: Does Imidin cause drowsiness or make you tired?

A: Official product information lists drowsiness as an uncommon side effect. Because the medicine can potentially cause visual disturbances and dizziness, patients should be mindful of these possible effects on their ability to perform tasks.

Q: Can older adults safely use Imidin?

A: Data regarding the use of Imidin in older adults are limited. While regulatory studies show that the medicine’s concentration in the blood may be slightly higher in older males, a general dose adjustment for age alone is not usually necessary. The drug is generally used cautiously in the older adult population, particularly when there are pre-existing health conditions.

Q: Is it normal to have a slight headache when starting Imidin?

A: According to the official product information, headache is listed as an uncommon adverse reaction associated with the medicine. It is a documented possibility.

Q: What happens if I miss a dose of Imidin?

A: If a dose is missed, regulatory instructions advise patients to take it as soon as they remember. However, if it is already close to the time for the next scheduled dose, skip the one you missed entirely. Regulatory guidance advises against taking two doses at the same time.

Q: Does Imidin affect liver function tests?

A: Official documents note that abnormal laboratory findings, such as an increase in gamma-GTP and triglycerides, are uncommon adverse reactions. Serious but rare adverse reactions, including hepatic dysfunction (liver damage), have also been reported.

Q: Can people with kidney problems take Imidin?

A: Use of the medicine requires caution in individuals with kidney problems. Official guidance mandates caution, and for individuals with severe renal impairment, a restriction on the maximum daily dose is required to help manage the drug's clearance from the body.

Q: Does Imidin interact with birth control pills?

A: Official interaction information notes that the medicine is processed by the CYP3A4 enzyme system. While specific hormonal contraceptives are not listed, other strong inhibitors of this enzyme are documented to increase the medicine’s plasma levels. Patients are generally advised to disclose all medicines, including contraceptives, to their healthcare provider.

Q: What are the known long-term risks associated with Imidin?

A: The most rigorous clinical trial data focus on short-term periods, typically about 12 weeks. While longer-term observational follow-up studies have been conducted, the official product information states that the long-term effects are not fully established by the same rigorous randomized comparison methods.

Q: Does Imidin affect sleep quality?

A: Official regulatory documents list drowsiness as an uncommon adverse reaction, which is a central nervous system effect. However, the label does not specifically list other sleep-related issues such as insomnia or restless sleep.

Q: Can Imidin interact with dietary supplements or herbal remedies?

A: The official patient information sheet advises users to inform their doctor about all medicinal products they are taking, which includes over-the-counter medicines, supplements, and herbal remedies, as potential interactions may need to be assessed.

Q: Why do doctors prescribe Imidin for multiple different conditions?

A: The medicine is approved and defined by its labeled indication, which is primarily for symptoms related to Overactive Bladder (OAB). This is because its mechanism of action is to block muscarinic receptors, which helps relax smooth muscles, such as those in the bladder.

Q: Is Imidin a controlled substance?

A: No. Official regulatory schedules, such as the U.S. Controlled Substances Act, do not list the active ingredient, Imidafenacin, as a controlled substance.

Q: How does Imidin interact with other medicines for chronic conditions?

A: The medicine has documented interactions with two main types of drugs: strong inhibitors of the CYP3A4 enzyme and other anticholinergic medicines. Taking these alongside Imidin may increase the risk of side effects like dry mouth or constipation. Patients are advised to review all their medications with a healthcare provider.

Q: Can Imidin be taken while breastfeeding?

A: Official guidance includes precautionary information related to breastfeeding. Official guidance recommends consultation with a healthcare professional to discuss the use of this medicine during breastfeeding.

Q: Does Imidin have different dosages for children versus adults?

A: Regulatory documents state that the safety and effectiveness of the medicine have not been established in pediatric patients, which includes children and adolescents. Therefore, only adult dosages are approved.

Q: Is Imidin an immunosuppressant?

A: No. Imidin is formally classified as an antimuscarinic agent. Its function is to block specific nerve signals to relax smooth muscles, primarily for bladder control. It does not work by suppressing the immune system.

Q: Is it safe to drive or operate machinery while taking Imidin?

A: Because this medicine may cause side effects such as visual disturbances, dizziness, and drowsiness, patients are advised to be aware of these possible effects before operating machinery or driving.

Q: What is the typical timeframe for a noticeable benefit from Imidin?

A: While the medicine reaches the bloodstream relatively quickly, clinical trials evaluating its effectiveness for Overactive Bladder symptoms typically monitored patients over an observation period of approximately 12 weeks to assess symptom changes.

Q: What are the less common, but serious, side effects of Imidin?

A: Official regulatory documents explicitly list serious adverse reactions that are rare but clinically significant. These include acute glaucoma (a severe eye condition), urinary retention (inability to empty the bladder), and hepatic dysfunction (liver damage).

How should Imidin be stored and disposed of?

How to Store and Dispose of Imidin?

Official regulatory guidelines strictly define the conditions required for storing and disposing of Imidin (Imidafenacin) tablets.

Storage Requirements

Imidin must be stored at room temperature and is required to be kept away from direct sunlight, excessive heat, and moisture. To protect the product from environmental degradation, the tablets must be kept in a tight container. A mandatory safety rule requires that this medicine is stored out of the reach of children at all times.

Disposal Instructions

For disposal, official labeling instructs patients to discard the remainder of the unused or expired medicine and not to store them. Disposal should be carried out in accordance with local environmental control regulations for pharmaceutical waste.

Imidin